These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20019699)

  • 1. Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.
    Liberti L; Breckenridge A; Eichler HG; Peterson R; McAuslane N; Walker S
    Clin Pharmacol Ther; 2010 Jan; 87(1):27-31. PubMed ID: 20019699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry.
    Anand R
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S33-9. PubMed ID: 12070360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in development and approval times for new therapeutics in the United States.
    Reichert JM
    Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closing the drug lag for new drug submission and review in Japan: An industry perspective.
    Poirier AF
    Clin Pharmacol Ther; 2015 Nov; 98(5):486-8. PubMed ID: 26239646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
    Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
    [No Abstract]   [Full Text] [Related]  

  • 6. [Innovative medicinal products: the new criteria of the Italian Medicines Agency.].
    Mammarella F; Tafuri G
    Recenti Prog Med; 2018 May; 109(5):261-262. PubMed ID: 29771247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 8. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drug approval tactician.
    Frantz S
    Nat Rev Drug Discov; 2003 Sep; 2(9):757. PubMed ID: 12953698
    [No Abstract]   [Full Text] [Related]  

  • 10. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry, manufacturing, and controls information in NDAs and ANDAs, supplements, annual reports, and other regulatory filings.
    Sheinin E; Williams R
    Pharm Res; 2002 Mar; 19(3):217-26. PubMed ID: 11934225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European regulatory perspectives for innovative therapies.
    Ormarsdottir S; Reginster JY; Abadie E
    Osteoporos Int; 2008 Jun; 19(6):725-31. PubMed ID: 18373059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regulatory consequences for the use of monoclonal antibodies].
    Lackner F; Behr-Gross ME
    Med Sci (Paris); 2009 Dec; 25(12):1183-8. PubMed ID: 20035703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory watch: Where do new medicines originate from in the EU?
    Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
    Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicines regulation and the pharmaceutical industry.
    Breckenridge A; Woods K
    BMJ; 2005 Oct; 331(7520):834-6. PubMed ID: 16210285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overhauling oversight--European drug legislation.
    Tsang L
    Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japan-Specific Key Regulatory Aspects for Development of New Biopharmaceutical Drug Products.
    Desai KG; Obayashi H; Colandene JD; Nesta DP
    J Pharm Sci; 2018 Jul; 107(7):1773-1786. PubMed ID: 29601839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
    Meron D
    Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.